Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2020
June 2020, Vol 11, No 3
June 2020, Vol 11, No 3
Early Detection of Cancer Feasible with Blood-Based Tests
By
Wayne Kuznar
Value-Based Care
June 2020, Vol 11, No 3
Two studies presented at the 2020 American Association for Cancer Research virtual annual meeting confirm the value of different liquid biopsies in the early detection of different types of cancer.
Read Article
Why Is COVID-19 More Aggressive in Certain Patients with Cancer?
By
Phoebe Starr
AACR Meeting Highlights
,
COVID-19
June 2020, Vol 11, No 3
At the 2020 virtual American Association for Cancer Research (AACR) annual meeting, part I, a team of oncologists from different COVID-19 hotspots around the world gave a snapshot of wisdom gleaned from their experience thus far. Understanding of COVID-19 is rapidly evolving; the summaries below represent the experience as of late April 2020.
Read Article
Impact of COVID-19 on Telehealth
AVBCC COVID-19 Webcast Series Coverage
,
COVID-19
June 2020, Vol 11, No 3
Telehealth (or telemedicine) has emerged as an essential component of healthcare during the COVID-19 crisis. In a recent webcast of the Association for Value-Based Cancer Care (AVBCC), a panel of experts discussed the current benefits and ongoing challenges of this technology, as well as its potential impact on patients and practices in the years to come.
Read Article
I-SPY 2: Durvalumab plus Olaparib and Paclitaxel Triplet in High-Risk Breast Cancer “Graduates” to Phase 3 Study
By
Phoebe Starr
Breast Cancer
June 2020, Vol 11, No 3
The combination of the checkpoint inhibitor durvalumab (Imfinzi), the poly ADP-ribose polymerase (PARP) inhibitor olaparib (Lynparza), and chemotherapy with paclitaxel used as neoadjuvant therapy improved the pathological complete response (pCR) of patients with high-risk HER2-negative stage II or III breast cancer compared with the physician’s choice of chemotherapy.
Read Article
Bispecific CAR T-Cells Show Promise in Children and Young Adults with Relapsed B-Cell ALL
By
Wayne Kuznar
AACR Meeting Highlights
June 2020, Vol 11, No 3
A bispecific chimeric antigen receptor (CAR) T-cell product directed against CD19 and CD22 antigens induced a complete response (CR) in 5 of 12 (42%) evaluable children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL).
Read Article
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
By
Phoebe Starr
AACR Meeting Highlights
June 2020, Vol 11, No 3
The addition of the checkpoint inhibitor atezolizumab (Tecentriq) to the 2 targeted therapies—the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib (Cotellic)—improved progression-free survival (PFS) and the duration of responses compared with the 2 targeted therapies plus placebo in patients with newly diagnosed advanced melanoma and
BRAF
V600E/K mutation, according to the phase 3 IMspire150 clinical trial.
Read Article
Two Ways to Target Tumors with KRAS Mutations
By
Wayne Kuznar
AACR Meeting Highlights
June 2020, Vol 11, No 3
Tumors with
KRAS
mutation are notoriously difficult to treat. Early data presented at the 2020 American Association for Cancer Research virtual annual meeting suggest 2 new routes for the treatment of cancers with
KRAS
mutation, including (1) the combination of a RAF/MEK inhibitor and a FAK inhibitor, and (2) the use of onvansertib, an investigational competitive inhibitor of the PLK1 enzyme, together with chemotherapy.
Read Article
Retevmo First Therapy Approved for 3 Types of Cancers with RET Mutations
FDA Approvals, News & Updates
June 2020, Vol 11, No 3
On May 8, 2020, the FDA accelerated the approval of a new kinase inhibitor, selpercatinib (Retevmo; Loxo Oncology) capsules, for the treatment of 3 types of cancer—metastatic non–small-cell lung cancer (NSCLC), metastatic medullary thyroid cancer, and other types of thyroid cancer—that are associated with
RET
gene mutations or fusions, as determined by an FDA-approved test. Selpercatinib is the first therapy approved specifically for the treatment of patients with cancer that is linked to
RET
mutations or fusions. The FDA granted selpercatinib breakthrough therapy and orphan drug designations.
Read Article
Tabrecta First FDA-Approved Targeted Therapy for Metastatic NSCLC and MET Exon 14 Skipping
FDA Approvals, News & Updates
June 2020, Vol 11, No 3
On May 6, 2020, the FDA accelerated the approval of oral capmatinib (Tabrecta; Novartis), a kinase inhibitor, for the treatment of adults with metastatic non–small-cell lung cancer (NSCLC). Capmatinib is the first agent approved by the FDA for the treatment of metastatic NSCLC associated with mutations that lead to mesenchymal-epithelial transition (MET) exon 14 skipping, as determined by an FDA-approved test. The FDA granted capmatinib breakthrough therapy and orphan drug designations.
Read Article
Pemazyre First FDA-Approved Therapy for Cholangiocarcinoma plus FGFR2 Fusion
FDA Approvals, News & Updates
June 2020, Vol 11, No 3
On April 17, 2020, the FDA approved pemigatinib (Pemazyre; Incyte), an oral kinase inhibitor, as the first treatment for adults (aged ≥18 years) with previously treated, locally advanced or metastatic cholangiocarcinoma that is associated with a fibroblast growth factor receptor 2 (
FGFR2
) gene fusion or other rearrangements, as detected by an FDA-approved test. This is the first targeted therapy approved for patients with advanced cholangiocarcinoma. Until now, the standard of therapy for this patient population has been chemotherapy combinations.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma